GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.21 (-0.19%)

Growth Price

Overvalued by 9.90%

Stability Price

Overvalued by 64.27%

Company Metrics

  • P/E 11.37
  • P/S 5.43
  • P/B 9.76
  • EPS 9.48
  • Cash ROIC 43.15%
  • Cash Ratio 1.76
  • Dividend 1.72 / 0.42%
  • Avg. Vol. 10.76M
  • Shares 1.65B
  • Market Cap. 158.18B

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Gilead Sciences, Inc., Biogen Inc andamp; Regeneron Pharmaceuticals: Morgan ...
Bidness ETC - Aug 28, 2015
Morgan Stanley analyst Matthew Harrison sees “opportunity” in Biogen Inc (NASDAQ:BIIB), Gilead Sciences, Inc. (NASDAQ:GILD) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) after the stocks dipped as a result of the recent market crash.
Why Gilead Sciences, Inc. Can Easily Take Over Bristol-Myers Squibb Co
Bidness ETC - Aug 27, 2015
Gilead Sciences, Inc. (NASDAQ:GILD) has accumulated a lot of cash during its exceptional stint as leader of the hepatitis C drug market.
Gilead Sciences share sales are stronger
Pulse Headlines - 23 hours ago
Gilead Sciences Inc. (NASDAQ: GILD), has a current market cap of 159.7B and has seen over the past 3 months 10675900 shares traded hands on daily basis at $123.62.
Biogen And Gilead Sciences Catch The Eye Of Short Sellers - Benzinga
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Sees Large Outflow of Money - American Trade Journal
Gilead Sciences, Inc. (GILD): Stock Update
Bidness ETC - Aug 21, 2015
Gilead Sciences Inc. (NASDAQ:GILD) stock has been volatile for quite some time now. It reached an all-time high in June at $123.37, only to crash in December to $85.95 apiece.
Gilead Sciences, Inc. Price Target Update - The Hullabaloo Online
3 Numbers Show Why Gilead Sciences Inc. Is in a Great Position Today
Motley Fool - Aug 15, 2015
Gilead Sciences (NASDAQ:GILD) recently reported Q2 earnings, and it was an exciting quarter for the company. Three numbers buried in the earnings call (quotes below are courtesy of S&P Capital IQ) really highlighted to me why Gilead Sciences is in a ...
Gilead Sciences, Inc. (NASDAQ:GILD) Price Target Update - News Watch International
Better Dividend Stock: Gilead Sciences Inc. vs. Amgen Inc.
Motley Fool - Aug 17, 2015
However, I think that Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are two biotech blue chips that are certainly worthy of your consideration for the dividend portion of your portfolio, as both of these companies have stellar financials that ...
Gilead Sciences, Inc. Astonishing Performance In HCV Market - Bidness ETC
Gilead Sciences, Inc. (NASDAQ:GILD) EVP - R&D and CSO Norbert Bischofberger ... -
Biotech Stocks: Here's Where to Get In- Gilead Sciences, Inc. (NASDAQ:GILD ...
Wall Street Point - Aug 28, 2015
On the trading floor, shares of Gilead Sciences, Inc. (NASDAQ:GILD) gained 0.96% to close at $107.99. The $156.98B company on August 20, 2015 announced that the company's Marketing Authorization Application (MAA) for an investigational, once-daily ...
Biotech Stocks Ravage With Bears: Exelixis, Inc. (NASDAQ:EXEL), Gilead ... - StreetWise Report
Exelixis Up on Swiss Approval of Advanced Melanoma Drug -
Trader's Buzzers: Gilead Sciences, Inc. (NASDAQ:GILD), BlackBerry Ltd (NASDAQ ...
wsnewspublishers - Aug 28, 2015
Gilead Sciences declared that the company's Marketing Authorization Application (MAA) for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 mg (R/F/TAF) has been ...
Top Wall Street Stories: Pfizer Inc. (NYSE:PFE), Gilead Sciences Inc. (NASDAQ ... - Stock Transcript
Stock Update (NASDAQ:GILD): Gilead Sciences, Inc.'s AMBITION Study Results ...
Smarter Analyst - Aug 26, 2015
Gilead Sciences, Inc. (NASDAQ:GILD) announced detailed results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMBrIsentan and Tadalafil in patients with pulmonary arterial hypertensION).
Investor's Alert - Gilead Sciences, Inc. (NASDAQ:GILD), Devon Energy Corp ... - wsnewspublishers
Gilead Sciences, Inc, Allergan PLC, Biogen Inc May Drive More Healthcare Mandamp;A
Bidness ETC - Aug 20, 2015
The healthcare industry saw an incredibly spiked rate of mergers and acquisitions this year, with $365 billion worth of deals signed by mid-August alone - a 65% increase over the same period last year.